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plantation, left ventricular assist device implantation). Repeatedly
measured levels of 8 biomarkers correlated with clinical outcomes
independent of clinical characteristics. Rates of change over timeReceived for publication April 10, 2020. Accepted August 10, 2020.
Corresponding author: Dr Isabella Kardys, Erasmus MC, University
Medical Center Rotterdam, Department of Cardiology, Room Na-316, PO
Box 2040, 3000 CA Rotterdam, The Netherlands. Tel.: þ31 6 50032051;
fax: þ31 10 704 4759.
E-mail: i.kardys@erasmusmc.nl
See page 1591 for disclosure information.
https://doi.org/10.1016/j.cjca.2020.08.010
0828-282X/ 2020 The Authors. Published by Elsevier Inc. on behalf of the Cana
license (http://creativecommons.org/licenses/by/4.0/).RESUME
Dans cette etude prospective d’une cohorte de 250 patients atteints d’
cardiaque stable, soumis à un prelèvement sanguin trimestriel, nous
avons etudie les associations entre 17 cytokines et recepteurs aux
cytokines mesures de façon repetee et les consequences cliniques au
cours d’un suivi median de 2.2 annees (25e-75e percentile, 1,4-2,5).
Soixante-six patients ont atteint le principal critère d’evaluation (indice
composite prenant en compte la mortalite cardiovasculaire, l’hospi-
talisation pour insuffisance cardiaque, la transplantation cardiaque,
l’implantation d’un dispositif d’assistance ventriculaire gauche). LesDuring the course of chronic heart failure (HF), levels of measured a broad range of cytokines and cytokine receptors
numerous proinflammatory cytokines are elevated even
without an acute stressor being present, which has led to the
hypothesis that inflammation plays a central role in the pro-
gression of HF.1 Many reports have suggested that cytokines
predict adverse outcome in these patients, but most of these
studies had limited sample size and lacked adjustment for
traditional biomarkers like N-terminal pro-B-type natriuretic
peptide (NT-proBNP), high-sensitivity troponin T, and C-
reactive protein (CRP).2 Moreover, to the best of our
knowledge, the temporal patterns of inflammatory proteins
other than CRP3 have not yet been investigated in patients
with stable HF. In the current study, we hypothesize that
protein level changes occur in the time period before an
incident adverse clinical event. To test this hypothesis, werepeatedly with a multiplex assay in patients with stable HF,
and investigated the association between their temporal
patterns and clinical outcome.
Methods
Between October 2011 and June 2013, a total of 263 pa-
tients were prospectively enrolled at 2 tertiary medical centres in
the Biomarker Measurements and New Echocardiographic
Techniques in Chronic Heart Failure Patients Result in
Tailored Prediction of Prognosis (Bio-SHiFT) study. Stable HF
patients were recruited during their regular outpatient clinic
visit, as described previously.4,5 In the current investigation,
only the 250 patients with HF with a reduced ejection fraction
were evaluated. Ambulatory patients were recruited during their
regular outpatient clinic visit, and these patients were stable as
defined by the fact that they had not been hospitalized for HF
in the past 3 months. The study was approved by the
responsible medical ethics committees and conducted in
accordance with the Declaration of Helsinki. Written informed
consent was obtained from all patients. The trial is registered in
ClinicalTrials.gov (NCT01851538; https://clinicaltrials.gov/
ct2/show/NCT01851538).dian Cardiovascular Society. This is an open access article under the CC BY
(slopes of biomarker evolutions) remained independently associated
with outcome for 15 biomarkers. Thus, temporal patterns of cytokines
and cytokine receptors, in particular tumour necrosis factor ligand
superfamily member 13B and interleukin-1 receptor type 1, might
contribute to personalized risk assessment.
niveaux de 8 biomarqueurs mesures de manière repetee etaient
correles avec les consequences cliniques, independamment des car-
acteristiques cliniques. Les taux de changement au cours du temps
(pentes d’evolution des biomarqueurs) sont restes independamment
associes aux pronostics pour 15 biomarqueurs. Ainsi, les modèles
temporels des cytokines et des recepteurs de cytokines, en particulier
le membre 13B de la superfamille des ligands du facteur de necrose
tumorale et le recepteur de l’interleukine-1 de type I, pourraient con-
tribuer à une evaluation personnalisee des risques.
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information is given in the Supplementary Material. We per-
formed blood sampling and medical evaluation at baseline and
this was repeated at each study follow-up visit. These visits were
predefined and scheduled every 3 months (1 month) with a
maximum of 10 study follow-up visits. For the current inves-
tigation, follow-up lasted until November 2015. The primary
end point (PE) was a composite of cardiac death, heart trans-
plantation, left ventricular assist device implantation, and hos-
pitalization for management of acute or worsened HF,
whichever occurred first. We collected 1984 ethyl-
enediaminetetraacetic acid (EDTA) plasma samples before
occurrence of the PE or censoring (9 [25th-75th percentile,
5-10] blood samples per patient) during this first inclusion
round of the Bio-SHiFT study. For reasons of efficiency, for
the current investigation, we selected all samples drawn at
baseline, the last sample available in patients in whom the PE
did not occur during follow-up, and the 2 samples available
before the PE (which, by design, were 3 months apart;
Supplemental Fig. S1). This selection was on the basis of
previous investigations in this cohort, which showed that levels
of several biomarkers change in months before the incident
adverse event, whereas event-free patients show stable
biomarker levels.4 Altogether, this resulted in 530 samples.
A total of 17 cytokines and cytokine receptors were
measured using the Cardiovascular panel III of Olink Prote-
omics AB, Uppsala, Sweden, in a batch-wise analysis of the
samples. Biomarkers were delivered in normalized protein
expression (NPX) units, which are relative units expressed on
a log2 scale in which 1 unit higher NPX thus represents a
doubling of the measured protein concentrations.
We used linear mixed effect models to plot the average
temporal pattern of the biomarkers for patients with and without
a PE during follow-up, and freedom from composite end point
was assessed using KaplaneMeier analysis. To estimate the as-
sociations between patient-specific repeated biomarker measure-
ments and the PE, we applied joint modelling (JM) analyses. JM
combines linear mixed effect models for temporal evolution of
the repeated measurements with relative risk models for the time-
to-event data.6 We studied the repeatedly measured biomarker
levels (including baseline and follow-up), as well as their rates of
change (ie, the slopes, which corresponds to the first derivative of
the longitudinal biomarker trajectories). First, all JM analyses
were performed univariably. Subsequently, we performed
multivariable analyses to adjust for potential confounders. We
applied a “clinical model,” which was adjusted for age, sex,
diabetes mellitus, atrial fibrillation, New York Heart Association
class, use of diuretics, and systolic blood pressure, and a “cardiac
biomarker model,” which was adjusted for baseline NT-proBNP,high-sensitivity troponin T, and CRP. Adjustments were made
in the relative risk and linear mixed effect model parts. For all JM
analyses, we used the Z-score (ie, the standardized form) of the
NPX values to allow for direct comparisons of different bio-
markers. Results are given as hazard ratios (HRs) and 95%
confidence intervals (CIs) per 1 SD difference of the repeatedly
measured biomarker level and per 0.1 SD per year difference of
the slope at any point in time during follow-up.
We used the conventional P < 0.05 threshold to conclude
significance for the relation between patient characteristics and
the occurrence of the PE during follow-up (Table 1). For the
other analyses, we corrected for multiple testing using the
Bonferroni correction (n ¼ 17), which resulted in a signifi-
cance level of P < 0.0029.
Results
Baseline characteristics and study end points
During a median follow-up of 2.2 (25th-75th percentile,
1.4-2.5) years, 66 patients (26%) reached the PE: 53 patients
were rehospitalized for acute or worsened HF, 3 patients
underwent heart transplantation, 2 patients underwent left
ventricular assist device placement, and 8 patients died from
cardiovascular causes. Overall, freedom from the composite
end point was 76  3% at 2 years of follow-up. Furthermore,
freedom from cardiovascular death was 89  2% at 2 years of
follow-up and freedom from HF hospitalization  standard
error was 80 3% at 2 years of follow-up (Supplemental
Figure S2). Table 1 shows the patients’ baseline characteris-
tics and the differences between patients who reached the PE
during follow-up and patients who did not. Overall, the
median age was 68 (25th-75th percentile, 58-76) years, 74%
were men, and median left ventricular ejection fraction was
30% (25th-75th percentile, 23%-37%).
Temporal patterns of circulating cytokine related
biomarkers in relation to study end points
Supplemental Figure S3 shows the average temporal
patterns of the biomarkers in patients with vs without the PE,
on the basis of linear mixed models. Twenty-four months
before occurrence of the end point, levels of C-C motif che-
mokine 15, tumour necrosis factor receptor 1, and tumour
necrosis factor receptor superfamily member 14 were already
higher in patients who ultimately reached the PE compared
with patients who remained event-free. Furthermore, these
biomarkers showed diverging patters as the end point drew
closer. Also, levels of C-C motif chemokine 16, C-X-C motif
chemokine 16, interleukin (IL)-1 receptor type 1 (IL-1RT1),
Table 1. Patient characteristics in relation to the occurrence of the primary end point
Variable Total
Primary end point reached during follow-up
PYes No
n 250 (100) 66 (26) 184 (74)
Demographic characteristics
Age, years 68 (58-76) 71 (60-79) 66 (58-74) 0.042*
Male sex 184 (74) 52 (79) 132 (71) 0.27
Clinical characteristics
Body mass index 27 (24-30) 27 (24-30) 27 (24-30) 0.78
Heart rate, bpm 67 (60-74) 70 (60-76) 66 (60-72) 0.26
Systolic blood pressure, mm Hg 120 (108-132) 115 (104-128) 122 (110-136) 0.021*
Diastolic blood pressure, mm Hg 72 (62-80) 70 (60-78) 74 (65-80) 0.052
Features of HF
Duration of HF, years 4.7 (1.7-9.8) 7.2 (3.2-13.1) 3.8 (1.1-7.9) < 0.001*
NYHA class III or IV 62 (25) 29 (44) 33 (18) < 0.001*
Left ventricular ejection fraction, % 30 (23-37) 25 (19-34) 30 (23-38) 0.035*
Traditional biomarkers
NT-proBNP, pmol/L 133 (45-274) 297 (176-525) 94 (29-205) < 0.001*
HsTnT, ng/L 18 (9-33) 30 (20-49) 14 (8-27) < 0.001*
CRP, mg/L 2.2 (0.9-4.9) 3.0 (1.4-5.4) 1.8 (0.7-4.3) 0.016*
Etiology of heart failure
Ischemic 116 (46) 36 (55) 80 (44) 0.097
Hypertension 31 (12) 8 (12) 23 (13)
Secondary to valvular disease 10 (4) 5 (8) 5 (3)
Cardiomyopathy 63 (25) 13 (20) 50 (27)
Unknown or other 30 (12) 4 (6) 26 (14)
Medical history
Known coronary artery diseasey 119 (48) 36 (55) 83 (46) 0.42
Previous percutaneous coronary intervention 81 (32) 26 (39) 55 (30) 0.16
Previous coronary artery bypass grafting 42 (17) 12 (18) 30 (16) 0.73
Previous CVA/TIA 39 (16) 14 (21) 25 (14) 0.14
Atrial fibrillation 97 (39) 33 (50) 64 (35) 0.030*
Diabetes Mellitus 77 (31) 29 (44) 48 (26) 0.007*
Hypercholesterolemia 94 (38) 29 (44) 65 (35) 0.22
Hypertension 113 (45) 34 (52) 79 (43) 0.23
COPD 31 (12) 12 (18) 19 (10) 0.097
Chronic inflammatory disease 23 (9) 9 (14) 14 (8) 0.26
Medication use
b-Blocker 225 (90) 57 (86) 168 (91) 0.25
ACE-I or ARB 235 (94) 59 (89) 176 (96) 0.076
Diuretics 227 (91) 64 (97) 163 (89) 0.043*
Loop diuretics 226 (90) 64 (97) 162 (88) 0.035*
Thiazides 6 (2) 3 (5) 3 (2) 0.19
Aldosterone antagonist 174 (70) 50 (76) 124 (67) 0.21
Aspirin 45 (18) 9 (14) 36 (20) 0.30
Vitamin K antagonist 193 (77) 56 (85) 137 (75) 0.084
Nitrates 43 (17) 14 (21) 29 (16) 0.31
Antiarrhythmics 46 (18) 16 (24) 30 (16) 0.15
Statins 144 (58) 41 (63) 103 (56) 0.32
Anti-inflammatory agents 26 (11) 9 (14) 17 (9) 0.26
KDOQI classification
eGFR  90 mL/min per 1.73 m2 28 (11) 7 (11) 21 (11) 0.59
eGFR 60-89 mL/min per 1.73 m2 92 (37) 20 (30) 72 (39)
eGFR 30-59 mL/min per 1.73 m2 110 (44) 33 (50) 77 (42)
eGFR < 30 mL/min per 1.73 m2 20 (8) 6 (9) 14 (8)
Non-normally distributed continuous variables are expressed as median (25th-75th percentile). Categorical variables are expressed as n (%).
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease;
CRP, C-reactive protein; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HF, heart failure, HsTnT, high-sensitivity troponin T;
KDOQI, National Kidney Foundation Kidney Disease Outcome Quality Initiative; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York
Heart Association; TIA, transitory ischemic attack.
* P < 0.05.
yKnown coronary artery disease was defined as stenosis  50%.
Bouwens et al. 1589
Serially Measured Cytokines in Stable HF PatientsIL-1 receptor type 2, IL-17 receptor A, IL-18-binding protein,
IL-2 receptor subunit alpha, lymphotoxin b receptor, tumour
necrosis factor receptor 2, and tumour necrosis factor ligand
superfamily member 13B (TNFSF13B) significantly increased
as the end point approached, but remained stable or showed a
divergent evolution in end point-free patients.Figure 1A shows the associations of the levels of the 17
repeatedly measured biomarkers with the PE on the basis of
JM analyses. In univariable analyses, repeatedly measured
levels of 13 of the biomarkers were positively associated with
the PE. Repeatedly measured levels of TNFSF13B showed the
strongest association with a HR of 3.18 (95% CI, 2.26-4.71)
p-value <0.0029 
(below significance level corrected for multiple testing)
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Figure 1. Associations of levels and slopes of cytokines and cytokine receptors with the primary end point. Hazard ratios (HRs) and 95% confidence
intervals (CIs) are given per 1 SD change in repeatedly measured biomarker level at any point in time during follow-up (A), and per 0.1 SD of the
annual slope at any point in time during follow-up (B). Crude model values were derived from Cox model unadjusted, and linear mixed effect (LME)
model, unadjusted; clinical model values were derived from Cox and LME models adjusted for age, sex, diabetes, atrial fibrillation, baseline New
York Heart Association class, diuretics, and systolic blood pressure, except for the model of TNFSF13B which was not adjusted for systolic blood
pressure because of convergence problems; cardiac biomarker model values were derived from Cox and LME models adjusted for baseline N-
terminal pro-B-type natriuretic peptide, high-sensitivity troponin T, and C-reactive protein. Slope analyses in crude and biomarker model were not
available for IL-1RT1 because of computational difficulties. C-C motif chemokine 15, C-C motif chemokine 15; CCL16, C-C motif chemokine 16;
CCL24, C-C motif chemokine 24; CXCL16, C-X-C motif chemokine 16; FAS, tumour necrosis factor receptor superfamily member 6; IL-18BP,
interleukin-18-binding protein; IL-17RA, interleukin-17 receptor A; IL2-RA, interleukin-2 receptor subunit alpha; IL-6RA, interleukin-6 receptor sub-
unit alpha; IL-1RT1, interleukin-1 receptor type 1; IL-1RT2, interleukin-1 receptor type 2; LTBR, lymphotoxin b receptor; TNF-R1, tumour necrosis
factor receptor 1; TNF-R2, tumour necrosis factor receptor 2; TNFRSF14, tumour necrosis factor receptor superfamily member 14; TNFRSF10C,
tumour necrosis factor receptor superfamily member 10C; TNFSF13B, tumour necrosis factor ligand superfamily member 13B.
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Serially Measured Cytokines in Stable HF Patientsper SD change at any point in time during follow-up. After
adjustment for clinical characteristics, the level of 8 repeatedly
measured biomarkers remained significantly associated with
the PE. IL-1RT1 showed the strongest association (HR, 3.04;
95% CI, 1.95-5.39), followed by TNFSF13B: HR, 3.01(95%
CI, 1.12-4.48), and tumour necrosis factor receptor 1: HR,
2.12 (95% CI, 1.55-2.92). The HR of TNFSF13B remained
significant and the highest (HR, 2.09; 95% CI, 1.49-2.99)
after adjustment for NT-proBNP, high-sensitivity troponin T,
and CRP, followed by the HR of IL-1RT1 (Fig. 1A). The
remaining biomarkers lost statistical significance after
adjustment for traditional cardiac biomarkers. Performance
measures of the models are shown in Supplemental Table S1.
The rates of change (ie, the slopes of the longitudinal
biomarker trajectories) in relation to risk of the PE, showed
significant, positive associations for all investigated biomarkers
except tumour necrosis factor receptor superfamily member 6
and IL-2 receptor subunit alpha in univariable analyses
(Fig. 1B). After adjustment for clinical characteristics, 15 of the
biomarkers still showed significant associations. C-X-C motif
chemokine 16 showed the numerically strongest association
with the PE with a HR of 1.62 (95% CI, 1.29-2.15) per 0.1
SD change of the annual slope after adjustment for clinical
factors.Discussion
Temporal patterns of several cytokines and cytokine re-
ceptors were associated with adverse events in 250 stable pa-
tients with HF, even after adjustment for clinical factors.
Proinflammatory cytokines are known for their important
roles in the disease process of HF. In a recent meta-analysis,
concentrations of tumour necrosis factor-a, IL-6, IL-1b,
and CRP were significantly higher in chronic HF patients
than in control participants, and serum IL-6 predicted mor-
tality.7 Recently, a study suggested that IL-32 is a novel
predictor of adverse cardiac events in HF patients after
myocardial infarction.8 Nevertheless, clinical trials targeting
different immune components have not resulted in improved
clinical outcomes; some interventions even resulted in wors-
ening of HF.9 Previous studies in chronic HF patients have
mostly described the value of single measurements of in-
flammatory markers (eg, at admission) for prognosis. To the
best of our knowledge, the temporal patterns of cytokine-
related biomarkers in patients with stable HF and their as-
sociations with clinical outcome have not yet been investi-
gated in detail. Repeated measurements could provide more
information on changes in marker levels over time and the
association between these changes and adverse clinical events.
Apart from the potential value for personalized risk assess-
ment, when investigated in more detail, these temporal pat-
terns might contribute to elucidation of aspects of immune
activation that contribute to the progression of HF.
Some limitations of our study warrant consideration.
Because of efficiency reasons, as described previously, we used
a subset of all available plasma samples. However, our previ-
ous investigations using all samples showed that most of the
examined biomarkers’ levels change before the incident
adverse event. Thus, we believe that with our approach we
retain the most informative measurements while enhancingefficiency. Furthermore, the current investigation focused on
HF with reduced ejection fraction patients only.
In conclusion, we showed that temporal patterns of several
cytokines and cytokine receptors are independently associated
with clinical adverse events in patients with stable HF. These
results suggest that repeated measurements of these bio-
markers, in addition to traditional cardiac biomarkers, might
contribute to personalized risk assessment and better identify
high-risk patients. Additionally, these findings might open
new avenues for druggable targets. Further studies that mea-
sure absolute biomarker concentrations repeatedly in larger
cohorts are needed to confirm and extend these findings.Funding Sources
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